Australian biopharmaceutical giant CSL Ltd said it would buy Swiss drugmaker Vifor Pharma AG for $11.7 billion, as it aims to diversify beyond its blood plasma collection business that took a hit from COVID-19 curbs.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
